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66 The Journal of Thoracic and Cardiobjective: The lung allocation score restructured the distribution of scarce donor
ungs for transplantation. The algorithm ranks waiting list patients according to
edical urgency and expected benefit after transplantation. The purpose of this
tudy was to evaluate the impact of the lung allocation score on short-term outcomes
fter lung transplantation.
ethods: A multicenter retrospective cohort study was performed with data from 5
cademic medical centers. Results of patients undergoing transplantation on the
asis of the lung allocation score (May 4, 2005 to May 3, 2006) were compared with
hose of patients receiving transplants the preceding year before the lung allocation
core was implemented (May 4, 2004, to May 3, 2005).
esults: The study reports on 341 patients (170 before the lung allocation score
nd 171 after). Waiting time decreased from 680.9  528.3 days to 445.6 
16.9 days (P  .001). Recipient diagnoses changed with an increase in
diopathic pulmonary fibrosis and a decrease in emphysema and cystic fibrosis
P  .002). Postoperatively, primary graft dysfunction increased from 14.1%
24/170) to 22.9% (39/171) (P  .04) and intensive care unit length of stay
ncreased from 5.7  6.7 days to 7.8  9.6 days (P  .04). Hospital mortality
nd 1-year survival were the same between groups (5.3% vs 5.3% and 90% vs
9%, respectively; P  .6)
onclusions: This multicenter retrospective review of short-term outcomes supports
he fact that the lung allocation score is achieving its objectives. The lung allocation
core reduced waiting time and altered the distribution of lung diseases for which
ransplantation was done on the basis of medical necessity. After transplantation,
ecipients have significantly higher rates of primary graft dysfunction and intensive
are unit lengths of stay. However, hospital mortality and 1-year survival have not
een adversely affected.
 
he lung allocation score (LAS) was implemented in May 2005 by the 
Procurement and Transplantation Network (OPTN).1 The LAS dramatically
changed lung allocation from a system based purely on waiting time to an
lgorithm based on survival probability on the waiting list and after transplantation.
he impetus for change was the scarcity of suitable donor lungs and the increasing
umber of deaths for patients on the waiting list.2-4
The OPTN began allocating lungs in 1990 on the basis of blood type and the
mount of time candidates had spent on the waiting list.5 In 1995, a minor chan
as made to this system when 90 days of waiting time were added for patients with
diopathic pulmonary fibrosis to offset the increased risk of mortality on the waiting
ist. In 1998, the Department of Health and Human Services published the Final
ule.6 This required the OPTN to emphasize the broader sharing of organs, reduce
vascular Surgery ● January 2008
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TXhe use of waiting time as an allocation criterion, and create
n allocation system based on objective medical criteria and
easures of medical urgency.
The LAS was developed by multivariate modeling and
as approved by the OPTN in 2004. The three main objec-
ives were as follows: (1) reduce the number of deaths on
he lung transplant waiting list, (2) increase transplant ben-
fit for lung recipients, and (3) ensure the efficient and
quitable allocation of lungs to active transplant candi-
ates.7 The LAS assigns a score to all candidates ove
ge of 12 years ranging from 0 to 100. It is a weighted
ombination of predicted risk of death during the following
ear on the waiting list and the predicted likelihood of
urvival during the first year after transplantation.
The purpose of this study was to evaluate the impact of
he LAS system on the waiting list and short-term outcomes
fter lung transplantation. Many lung transplant surgeons
ave the impression that the LAS has increased the com-
lexity of the cases and their complication rates. Our hy-
othesis was that the LAS would decrease waiting time for
ecipients but would also increase morbidity and mortality
fter transplantation.
atients and Methods
ransplant Recipients
multicenter retrospective cohort study was performed with data
rom five academic medical centers: University of Virginia, Wash-
ngton University, University of Southern California, University of
isconsin, and the Mayo Clinic. The two cohorts were patients
ndergoing transplantation the year preceding the introduction of
he LAS (May 4, 2004, to May 3, 2005) (pre-LAS group) and
atients undergoing transplantation the year after the LAS was
mplemented (May 4, 2005, to May 3, 2006) (LAS group). In an
ffort to compare the severity of illness between the groups, the
AS was calculated for the pre-LAS group using the appropriate
Abbreviations and Acronyms
ICU  intensive care unit
LAS  lung allocation score
OPTN Organ Procurement and Transplantation
Network
ABLE 1. Baseline characteristics
Pre-LAS (
ge (y) 49.2
ender (female) 80 (
rocedure (bilateral lung transplant) 111 (
etransplantation 3 (
schemic time (first lung in minutes) 285.2
AS 35.4AS, Lung allocation score.
The Journal of Thoracicariables available close to the time of transplant. Primary graft
ysfunction was defined according to the International Society of
eart and Lung Transplantation definition: arterial oxygen tension/
nspired oxygen fraction less than 300 and a chest radiograph with
 characteristic diffuse bilateral infiltrate.8 The human studie
ommittees at each institution granted approval for this research.
aiting List Estimates
ata from the waiting lists at the five institutions were gathered for
he same two groups. To calculate the percentage of patients dying
n the waiting list, we estimated the size of the waiting list for both
roups. Because the waiting lists are dynamic, this is not a straight-
orward process. We identified the actual number of patients on the
aiting lists at 4 interval time points for both cohorts (May 15,
ugust 15, November 15, and February 15). These numbers were
veraged (total number divided by 4) to estimate the size (denom-
nator) of the waiting list. The numerator was the actual number of
atients who died on the waiting lists.
tatistical Analysis
ategorical variables were compared by the 2 test. Continuous
ariables were compared with the Student t test or Kruskal–Wallis
est where appropriate. Estimates of the cumulative death rate at 1
ear were calculated by the Kaplan–Meier method, and the sur-
ival differences between the pre-LAS and LAS groups were
ssessed by the log–rank test. Short-term results were controlled
or diagnosis by the Mantel–Haenszel test. All data analysis was
erformed with SAS 9.1.3 software (SAS Institute, Inc, Cary, NC).
esults
atient Characteristics
here were 170 patients in the pre-LAS group and 171 in
he LAS group. The numbers of patients per group from
ach institution were as follows: Washington University 59
nd 52, University of Southern California 37 and 38, Uni-
ersity of Virginia 31 and 35, University of Wisconsin 34
nd 33, and Mayo Clinic 9 and 13. The baseline character-
stics are listed in Table 1. The pre-LAS group had 
etransplants and a lower calculated LAS (P  .05). The
ecipient diagnoses changed significantly with the initiation
f the LAS (Table 2). There were an increase in the n
f patients with idiopathic pulmonary fibrosis and a de-
rease in patients with chronic obstructive pulmonary dis-
ase and cystic fibrosis (P  .002).
170) LAS (n  171) P value
51.2 13.0 .16
) 80 (46.8%) .96
) 106 (62.0%) .2
10 (5.8%) .05
271.0 99.4 .20
42.5 15.2 .001n 
14.0
47.1%
65.3%
1.8%)
97.9
8.2and Cardiovascular Surgery ● Volume 135, Number 1 167
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1
TXaiting List
mplementation of the LAS reduced the waiting time for
ransplant recipients (680.9  528.3 days for pre-LAS vs
45.6  516.9 days for LAS; P  .001). The percentage of
atients dying on the waiting list decreased from 15.3%
74/485) for the pre-LAS group to 11.3% (51/450) for the
AS group (P  .08). However, the absolute number of
atients dying on the waiting list decreased from 74 to 51,
30% decrease.
urgical Morbidity
urgical morbidity is illustrated in Table 3. Primary 
ysfunction was higher in the LAS group (P  .04). The
otal number of days mechanically ventilated and lengths of
tay in the intensive care unit (ICU) were also higher in the
AS group (3.3  5.1 days vs 6.8  14.4 days; P  .004;
nd 5.7  6.7 days vs 7.8  9.3 days; P  .02, respec-
ively). However, the total number of hospital days was
imilar between the two groups (22.8  34.0 days vs 22.2
22.5 days; P  .86).
To determine whether elevated pulmonary artery pres-
ure was associated with primary graft dysfunction, we
ompared the mean and systolic pulmonary artery pressures
etween the groups and between those patients with and
ithout graft dysfunction. The mean and systolic pulmo-
ary artery pressures were similar between the pre-LAS and
AS groups (27.5 vs 28.9 mm Hg and 40.1 vs 43.7 mm Hg,
espectively (P  .19). In addition, there was a trend but no
ignificant relationship between systolic pulmonary artery
ressure and the presence of graft failure in this study (41.2
s 50.5 mm Hg; P  .14).
ABLE 2. Recipient diagnosis
Pre-LAS (n
tiology of end-stage lung disease
COPD 78 (45.
Cystic fibrosis 39 (22.
Idiopathic pulmonary fibrosis 25 (14.
Pulmonary hypertension 7 (4.1
Other 21 (12.
AS, Lung allocation score; COPD, chronic obstructive pulmonary disease
ABLE 3. Perioperative morbidity
Pre-LAS (n  170
rimary graft dysfunction 24 (14.1%)
CMO 8 (4.7%)
eoperation 19 (11.2%)
irway complications 9 (6.4%)
ialysis 10 (6.0%)
eintubation 32 (19.3%)AS, Lung allocation score; ECMO, extracorporeal membrane oxygenation.
68 The Journal of Thoracic and Cardiovascular Surgery ● JanuWhen the groups were adjusted for diagnosis, primary
raft dysfunction and days mechanically ventilated were no
onger associated with group (P  .2). When the rates of
rimary graft dysfunction for patients with pulmonary fi-
rosis were examined, there was no significant difference
etween the groups (32% [8/25] vs 22% [9/41]; P  .4).
owever, ICU length of stay continued to be associated
ith group (P  .04).
ortality
erioperative mortality was defined as a death within 30
ays of transplantation or during the same hospitalization.
erioperative mortality was not different between the two
roups (5.3% [9/170] vs 5.3% [9/171]; P  .99). The
aplan–Meier 1-year survival was also similar between the
wo groups (86.4% vs 89.9%; P  .6).
onclusions
he LAS significantly changed the allocation process for
onor lungs in the United States. It was initiated because the
revious system, based on waiting time, failed to accom-
odate patients with a rapidly deteriorating course who
ould not tolerate the prolonged waiting times and who
ere more likely to die on the waiting list.2,9,10 The LAS
lgorithm attempts to balance waiting list urgency with
osttransplant survival. Because these vary among patients
ith different lung diseases, diagnosis is included as a
ariable in the LAS calculation. This report demonstrates a
arked shift in the lung diseases being treated by transplan-
ation with an increase in idiopathic pulmonary fibrosis and
0) LAS (n  171) P value
58 (33.9%)
22 (12.9%)
42 (24.6%) .002
4 (2.3%)
45 (26.3%)
LAS (n  171) P value
39 (22.9%) .04
7 (4.1%) .78
25 (14.3%) .32
10 (7.8%) .67
11 (6.4%) .84
26 (15.9%) .41 17
9%)
9%)
7%)
%)
4%))ary 2008
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TXdecrease in cystic fibrosis and emphysema. These changes
re consistent with the goals of the LAS inasmuch as
atients with idiopathic pulmonary fibrosis had a higher
ortality on the waiting list under the previous allocation
ystem.4,10 However, this contradicts an earlier report 
ingaraju and colleagues,11 which simulated the effects 
he LAS on the lung diseases being treated by transplanta-
ion. Their simulation showed that patients with pulmonary
brosis had improved rankings and patients with emphy-
ema had worse rankings but the number of transplants for
ach disease category did not change significantly.
Importantly, our results demonstrate that the LAS re-
uced the waiting time for transplantation by 35% (P 
001). It will be very interesting to see whether this is
ustainable as data from the LAS system mature. One could
ypothesize that if the number of donor lungs remains fixed,
icker patients will populate the waiting list and waiting
imes may begin to increase over time. Our data would not
eflect this inasmuch as there was a significant increase in
he number of patients with pulmonary fibrosis receiving
ransplants during the first year of the LAS system.
Our estimation of the percent of patients dying on the
aiting list showed that the LAS group may have fewer
eaths (15.3% [74/485] pre-LAS group vs 11.3% [51/450]
AS group; P .08). The true number is dynamic and very
ifficult to identify precisely. If one looks only at the
umber of deaths on the waiting list, it is not easy to
ompare groups because the denominator, the total number
f patients on the waiting list, is unknown. However, the
bsolute number of patients dying on the waiting list did
ecrease from 74 to 51, a 30% decrease.
In addition, there are patients listed now who would never
ave been listed before because they had little chance of
urviving on the waiting list in the old system. These “sick”
atients might die on the waiting list in the new LAS system,
ut they would never have been listed in the old system. In this
ay, the LAS system might inflate death rates. On the other
and, the old system denominator was inflated with relatively
ealthier patients with emphysema who had little chance of
ndergoing transplantation in the current LAS system. It is
uite likely that these patients are not even listed now because
hey would have a low LAS and placing them on the list to
ccrue time is no longer advantageous. Thus, the change in
ystems not only changes who dies on the waiting list, but it
lso changes who is listed in the first place, thus making a
ifference in mortality very difficult to interpret.
The pre-LAS and LAS groups were comparable with
espect to age, gender, procedure performed, and ischemic
ime (Table 1). However, the score of the LAS group
ore retransplants and a higher LAS than had the calculated
core for the pre-LAS group. This is an expected difference
ecause the donor lungs in the LAS group were allocated to
atients with higher LASs. The International Society of
The Journal of Thoracicd
eart and Lung Transplantation, along with other reported
eries, have identified retransplantation as a significant risk
actor for primary graft dysfunction.12,13 In addition, diag-
oses of pulmonary fibrosis and pulmonary hypertension
re established risk factors for the development of primary
raft dysfunction. Our data demonstrate that as the number
f transplants for pulmonary fibrosis increased, so did the
ates of primary graft dysfunction. However, when we con-
rolled for diagnoses, the rates of primary graft dysfunction
ere no longer different between the groups. Therefore, much
f the increased morbidity seen in the LAS group is due to the
hift in lung diseases being treated by transplantation.
The increase in primary graft dysfunction with the LAS
roup explains the doubling of the length of mechanical
entilation and the increase in ICU length of stay. Interest-
ngly, although primary graft dysfunction is the most im-
ortant predictor of postoperative mortality and was present
n almost 25% of the LAS group, there was no difference in
ortality between the cohorts in the study.14 In fact, th
ortality for both groups was only 5.3% (P .99). It is also
mportant to note that there was no significant relationship
etween elevated pulmonary artery pressure and primary
raft dysfunction in this study.
imitations of the Study
imitations of this study are that it is a retrospective review
ith a short follow-up. The real impact of the LAS will not
e realized for several years. It is important to understand
hat the LAS system is dynamic. It was designed to update
he models every 6 months to include the most recent data
ith at least 3 years of follow-up.5
In conclusion, this multicenter retrospective study of
hort-term outcomes supports that the LAS is achieving its
bjectives. The LAS has reduced waiting time and altered
he lung diseases being treated by transplantation. Although
ransplant recipients have higher rates of primary graft
ysfunction and longer stays in the ICU, the overall hospital
tay and mortality are not affected. However, we do not
now whether the LAS will reduce mortality on the waiting
ist and what the long-term effects of these changes will be.
e do know that if the LAS system increases the rates of
rimary graft dysfunction and the length of ICU stay, it will
ncrease the medical and financial resources required to care
or these patients. Finally, despite increased morbidity, the
-year survival approached 90% in the LAS group. This is
n excellent early result for a sick group of patients, but
onger follow-up is needed to draw definitive conclusions
bout the success of the LAS system and to modify the
lgorithm with more comprehensive data.
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iscussion
r Kenneth R. McCurry (Pittsburgh, Pa). I congratulate Dr
ozower and his colleagues on their work. I think the impact of the
AS on posttransplant outcomes as well as waiting list mortality
re critical issues that deserve a great deal of attention. This paper
s the first to address both sides of this equation in a comprehensive
ashion.
Dr Kozower and his colleagues have presented data from their
ve institutions demonstrating a significant change in the distri-
ution of lung transplants by recipient diagnosis since implemen-
ation of the LAS system, with an increase in the percentage of
ransplants being performed for idiopathic pulmonary fibrosis from
5% to 25% and a concomitant decrease in the percentage of
ransplants being performed for chronic obstructive pulmonary
isease from 46% to 34%. As Dr Kozower has stated, these data
re certainly anticipated and indeed the intended effect of the LAS
ystem. They are also consistent with, although somewhat less t
70 The Journal of Thoracic and Cardiovascular Surgery ● Januramatic than, the initial 6-month analysis of United Network for
rgan Sharing data in October of 2005, where about 46% of the
ransplants performed in the United States during the first 6 months
fter initiation of the LAS were performed for restrictive lung
isease. At our own center in Pittsburgh, approximately 35% of
ur patients received transplants for idiopathic pulmonary fibrosis
ompared with about 18% previously. This distribution will obvi-
usly vary a little bit depending on the local referral practices and
he associated medical programs.
Also, interestingly, 2 weeks ago at the annual meeting of the
nternational Society for Heart and Lung Transplantation, the
ohns Hopkins Lung Transplant Program presented an abstract
valuating global US 1-year survival under the new LAS system.
n their published abstract, they reported on 1486 lung transplants
hat were performed in the United States from May 4, 2005, which
as the start date of the LAS system, through July 15, 2006. In the
roup of patients with an LAS less than 44, they found a 1-year
urvival of 73%, whereas the group with an LAS greater than or
qual to 44.4 had a significantly lower 1-year survival of approx-
mately 56%. In the five academic medical centers represented in
r Kozower’s paper, the mean LAS in the LAS era was 42 15.2,
et they had a 1-year survival of 86.4%. These are certainly
xcellent outcomes and the centers represented should be congrat-
lated in that regard. This discrepancy does, however, raise the
uestion of whether these excellent outcomes can be universally
chieved in the undoubtedly sicker patient population that is and
ill receive transplantation under the LAS system now and in the
uture. As Dr Kozower has noted, however, the design of the LAS
ystem was not only to consider the medical urgency of potential
ecipients, that is, those most likely to die without a transplant, but
lso to consider net transplant benefit, taking into consideration
osttransplant survival as well as waiting list mortality. Thus, it is
mperative to evaluate the effect of the LAS system on waiting list
ortality, as you have done.
Intuitively, and certainly from personal experience, I do believe
hat the waiting list mortality has declined under the LAS system.
ndeed, I believe that in 2005, when the LAS system was imple-
ented in the United States, there were about 350 deaths on the
aiting list that year compared with about 500 per year for the
revious 4 to 5 years. I do, however, have a question regarding the
ethodology that you used to calculate waiting list mortality in
our paper. You describe estimating the denominator by determin-
ng the number of patients on the waiting list at 4 different time
oints and then averaging these numbers to determine the average
umber of patients waiting over the year, while the numerator was
he actual numbers of deaths while waiting. This method does not
ake into account those patients who were removed from the
aiting list owing to progression of disease to a point of not being
ransplantable. This event would also be a failure, I would think, of
hatever allocation system was in place at the time. Would it not
ave been simpler and indeed more thorough to determine the fate
f each patient who was on the waiting list over the study period?
n this fashion, there would be four possible outcomes for each
atient—transplantation, death waiting, removed from the list ow-
ng to progression of disease, or continued waiting on the list—to
llow a more clear understanding of what happens to patients on
he lung transplantation waiting list.
ary 2008
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Kozower et al Cardiothoracic TransplantationDr Kozower. Thank you for your comments and for an excel-
ent first question. I agree with you that it would definitely be more
horough to evaluate the outcome for every patient who was listed
or transplant. However, I am not sure it would be simpler. With
his retrospective cohort design, it was difficult for us to determine
ow many patients were on the list at specific time points, and
ome centers do not have records of patients listed for transplan-
ation. Given these limitations, our method of determining how
any patients were on the waiting lists seems reasonable.
Dr McCurry. I think it is going to be a critical issue going
orward.
My second question is, in your presentation you reported
hat the rate of primary graft dysfunction as well as days of
echanical ventilation and days in the ICU were significantly
reater in the LAS era than in the pre-LAS era, although only
CU length of stay remained significant after adjustment for
iagnosis. Can you expand on the grade of primary graft dys-
unction that you included in your paper? As you know, the
nternational Society for Heart ad Lung Transplantation now
as 4 different grades, 0 through 3, for primary graft dysfunc-
ion. Also, can you expand on why you think this rate was
ncreased in the LAS era? Did you look at other potential
ecipient confounding factors, such as presence of pulmonary
ypertension, use of cardiopulmonary bypass, or transfusion
equirements? Did you look at donor demographics to assure
hat they were equal between the two groups?
Dr Kozower. We defined primary graft dysfunction as grades
and 3, that is, an arterial oxygen tension/inspired oxygen fraction
ess than 300 and a chest radiograph with the diffuse infiltrates.
his occurred within the first 3 days. As to why patients in the LAS
ra had more primary graft dysfunction, I think for our series much
f that was shown to be due to the increase in patients requiring
ransplantation for idiopathic pulmonary fibrosis. L
The Journal of ThoracicThe third part of your question is a good one. We did not look
t pulmonary artery pressures in both groups, but that is included
n the LAS score, which was higher in the LAS group. We did look
t the use of cardiopulmonary bypass and it was quite similar
etween the two groups. In the pre-LAS era it was 34%, and for
he LAS group it was 37%, with a P value of .8.
Dr McCurry. Finally, what is your clinical impression as to
hy ICU stay was prolonged? Were there more infectious com-
lications in the sicker patient population in the LAS, or did you
ave more patients who were in the hospital awaiting transplan-
ation preoperatively? What was your clinical impression as to
hy they stayed in the ICU longer?
Dr Kozower. My clinical impression is that these patients are
efinitely sicker preoperatively. We have shown that there was a
ignificant increase in the LAS between the groups. You raise an
xcellent point about infectious complications and in-house pa-
ients, but we did not collect those data.
Dr Thomas M. Egan (Chapel Hill, NC). I congratulate you
nd your other institutions for outstanding results in sicker
atients.
I want to echo Dr McCurry’s comment about pulmonary hy-
ertension. Presumably, you did not change your donor acceptance
riteria from 1 year to the next, and so the incidence of primary
raft failure has to be recipient factors and not donor factors. That
ould imply that you have to look at what the donor factors were.
lthough you did not show a difference in diagnosis, my bet would
e that there is a difference in pulmonary pressures in those
atients, and pulmonary hypertension is a risk factor for primary
raft dysfunction.
Dr Kozower. I agree with you, Dr Egan. We did not examine
ulmonary artery pressure independently, but it is included in the
AS algorithm, which was increased in the LAS group.
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